Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-06-25 00:00:00 ET · period of report 2024-06-24 · accession 0001883850-24-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-25 | 2024-06-24 | REGN | LAROSA JOSEPH J | EVP GC, Secret | F - Tax | $1,060.13 | -11.1K | 39.8K | -22% | -$11.75M |
| D | 2024-06-25 | 2024-06-24 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $555.67 | +14.4K | 50.9K | +40% | +$8.03M |
| D | 2024-06-25 | 2024-06-24 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $0.00 | -14.4K | 14.4K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-24 | F | D | 11,084 | $1,060.13 | 39,803 | D | — | — | |
| 2 | Common | Common Stock | 2024-06-24 | M | A | 14,450 | $555.67 | 50,887 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-06-24 | M | D | 14,450 | $0.00 | 14,450 | D | $555.67 · — to 2025-12-16 | 14,450 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |